CELC — Q2 2026 Financial Report Analysis

Celcuity's second quarter of 2026 was the last one before it became a company that sells a drug. Its net loss widened to $78.9 million from $45.3 million a year earlier. Three things drove that: spending to hire and equip a sales force ahead of launch, a one-time $11.5 million charge for paying off its term loan early, and higher interest costs. It still had no revenue. What changed the picture came after the quarter closed: on July 14 the FDA approved gedatolisib, now sold as REVTORPYK, for one group of advanced breast cancer patients. In June the company also raised $575 million in low-interest convertible debt, which pays for the launch. Celcuity says its cash will last "at least into 2029."

At a glance

• $754.0 million in cash and short-term investments at June 30, up from $441.5 million at year-end. About $704 million is left once the $50 million approval payment owed to Pfizer is deducted. That is roughly 13 quarters at the current burn rate.
• SG&A rose 361% to $35.0 million. SG&A (selling, general and administrative expenses) is the cost of running and selling, as opposed to research. Of the $27.4 million increase, $23.4 million was tied to commercial hiring and launch preparation, so the spending moved from labs toward selling.
• The net loss per share was $1.44, versus $1.04 a year ago. Excluding non-cash items and the loan-payoff charge, the adjusted loss was $1.07 versus $0.93. Most of the gap between the GAAP and adjusted figures is the one-time $11.5 million debt charge.

The numbers

Year-ago SG&A and R&D reflect the company's reclassification of some prior-period costs from R&D to SG&A. "Non-GAAP adjusted" is the company's own measure. It excludes stock-based pay, non-cash interest, non-cash investment income and the debt payoff loss.

Where the money went

R&D fell because the big trial is winding down. Research and development spending was $31.1 million, down $5.3 million. The 10-Q gives two reasons: a $7.0 million drop in clinical trial costs, "primarily driven by decreased costs for the VIKTORIA-1 Phase 3 clinical trial," and the absence of a $5.0 million milestone payment to Pfizer that was booked in Q2 2025 when the drug application was filed. Partly offsetting those, employee and consulting costs rose $3.8 million and manufacturing and other costs rose $2.9 million. The manufacturing increase is the kind of spending you would expect while building inventory before a launch.

SG&A is now the largest cost. At $35.0 million, selling and administrative spending exceeded R&D for the first time on this comparison. It also doubled from Q1 2026, when it was about $17.4 million (the six-month total of $52.5 million minus Q2). The company says $14.5 million of the year-on-year increase was employee costs, "primarily driven by the hiring of additional personnel within our commercial function." Another $10.8 million went to pre-launch consulting, professional fees and infrastructure. Management also says the commercial build-out "is complete." If so, the jump in this cost line should mostly be over, and future quarters should look roughly like this one rather than doubling again.

Below the operating line, the debt refinancing cost $11.5 million. On June 8 Celcuity used $137.4 million of the new convertible note proceeds to repay its Oxford/Innovatus term loan in full. The early payoff forced it to write off $7.3 million of unamortized loan discounts and pay exit fees, which together make up the $11.5 million loss on extinguishment. This is a one-time accounting charge. In exchange, the company replaced a secured term loan with unsecured notes paying 0.25% interest.

What the FDA approval does, and doesn't, cover

REVTORPYK is approved in combination with fulvestrant, with or without palbociclib (two existing breast cancer drugs). The patients it covers have HR+/HER2- advanced breast cancer whose tumors do not carry a PIK3CA mutation, and who have already progressed on hormone therapy. HR+/HER2- is the most common breast cancer type: tumors fuelled by hormones and without high levels of the HER2 protein. The company says this group is "tens of thousands of patients" a year. The NCCN treatment guidelines, which many US oncologists and insurers rely on, list it as a "preferred Category 1" second-line option. That is the guidelines' highest recommendation.

The second half of the market is patients whose tumors do carry the PIK3CA mutation, which the company puts at about 40% of HR+/HER2- cases. REVTORPYK is not yet approved for them. In that trial cohort, gedatolisib plus fulvestrant and palbociclib cut the risk of progression or death by 50% versus alpelisib plus fulvestrant, an existing PIK3CA-targeted treatment (median 11.1 vs 5.6 months without the cancer worsening). Celcuity submitted a supplemental application (sNDA) for this group on August 26, 2026, after the quarter ended.

Commercial shipments started on schedule. On September 30 the company announced REVTORPYK was commercially available in the US, matching the "late in the third quarter" target in the Q2 release.

What the headline numbers hide

• Cash burn is steadier than the loss suggests. The loss grew 74%, but cash used in operations was $55.4 million in Q2, against about $55.1 million in Q1 (the six-month total of $110.5 million minus Q2). The $20.2 million gap between the GAAP loss ($78.9 million) and the adjusted loss ($58.7 million) is mostly the $11.5 million debt charge, plus $6.9 million of stock-based pay and $1.5 million of non-cash interest. None of these used cash in the quarter.
• A $50 million cash payment is already owed but hasn't left the account. FDA approval triggered a $50 million milestone payment to Pfizer, due within 60 days of July 14. Because the approval confirmed an obligation that already existed at June 30, Celcuity booked it as a $50 million liability and a matching $50 million intangible asset on the June balance sheet. The cash only goes out in Q3, so the true starting point for runway math is about $704 million, not $754 million. Pfizer is also owed low-to-mid-teens percentage royalties on every sale, and up to $180 million more in sales-based milestones. Gross profit on REVTORPYK will therefore be noticeably below its list-price revenue.
• The balance sheet now carries more debt than cash. Convertible notes total $776.25 million of face value: $201.25 million at 2.75% due 2031 and $575 million at 0.25% due 2032. That is more than the $754.0 million in cash and investments. Stockholders' equity turned slightly negative (-$12.8 million). The cost of carrying the debt is low, though. At the stated coupons, cash interest is roughly $7 million a year, and the company earned $4.2 million of interest income on its cash in Q2 alone.
• The convertible notes are future dilution. A convertible note can be swapped for shares instead of being repaid in cash. If both series converted in full at their initial rates, holders would receive about 8.5 million new shares (3.9 million at $51.30 per share for the 2031 notes, 4.6 million at $124.53 for the 2032 notes). That is equal to roughly 17% of the 48.9 million common shares outstanding at June 30. The share count has already risen: the weighted average used for per-share figures was 25.5% higher than a year earlier (54.8 million vs 43.7 million, including pre-funded warrants), mainly from the July 2025 equity raise. That is why the loss per share widened less (38%) than the total loss (74%).
• Guidance hasn't changed. The only financial guidance is the cash runway "at least into 2029," and it held even as management said R&D and SG&A "will increase" with the launch and the ongoing VIKTORIA-2 and prostate cancer trials. The company gives no revenue forecast.

Takeaway: The widening loss is the cost of building a sales force, and it was expected. What matters more is that Celcuity reaches launch with about $704 million of usable cash and a quarterly cash burn of about $55 million, so it does not need to sell shares to fund the REVTORPYK rollout. It paid for that by issuing $776 million of convertible debt that could become about 17% more shares. The next few quarters will show how quickly prescriptions grow, after Pfizer's mid-teens royalty, to start closing that gap.

What to watch next

• First revenue in Q3 2026 results (expected around mid-November). Shipments only began around September 30, so Q3 sales will be very small. Q4, the first full quarter of sales, is the first real read on demand. The Q3 report should also be the first to show the $50 million Pfizer payment leaving cash and the intangible asset starting to amortize, now that the drug has launched.
• The PIK3CA-mutant sNDA. It was submitted in August. The company has not said whether the FDA accepted it or what the decision date is. That date is the next regulatory catalyst, because approval would roughly double the patient population REVTORPYK can be prescribed for.
• Cost trajectory. With the commercial build-out described as complete, SG&A should level off around the Q2 run-rate. R&D will depend on how fast VIKTORIA-2 enrolls. That first-line trial was expanded in Q2 to add a second study in hormone-sensitive patients, which adds cost and widens the potential market.
• More data in Q4 2026. Management expects to present updated VIKTORIA-1 results from both cohorts and updated prostate cancer (mCRPC) data, with more detail on that program's strategy, at medical conferences in the fourth quarter.

Our read: the runway claim holds up on the numbers. About $704 million against roughly $220 million a year of current cash burn is a little over three years, before any sales. That leaves room for operating costs to rise with the new trials and still reach 2029. The open question for the stock is how fast sales ramp, not whether the company runs out of money.